{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:53:15Z","timestamp":1780372395858,"version":"3.54.1"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Apremilast, a phosphodiesterase-4 inhibitor, has shown promise to have a potential beneficial metabolic effect. We conducted a single-centre retrospective study on adult patients with moderate-to-severe psoriasis who underwent apremilast treatment over at least 12 and 52 weeks, respectively. Baseline characteristics, weight, lipid profile, and fasting glucose levels were collected at baseline and at 12, 24, and 52 weeks. Furthermore, we conducted a narrative review of the current scientific knowledge on the metabolic effects of apremilast in patients with psoriasis and psoriatic arthritis. We observed a significant reduction in average weight and body mass index (BMI) in patients treated with apremilast in both the initial and the subgroup analysis, a significant reduction in triglycerides levels at 24 and 52 weeks, and a significant increase in high-density lipoprotein (HDL) levels at 52 weeks, whereas there were no significant changes in total cholesterol or low-density lipoprotein (LDL) concentrations over the 52-week treatment period. These findings suggest a potential positive impact of apremilast on both weight management and lipid profile in individuals with moderate-to-severe psoriasis in the medium\u2013long term.<\/jats:p>","DOI":"10.3390\/life14030395","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T05:14:07Z","timestamp":1710738847000},"page":"395","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience"],"prefix":"10.3390","volume":"14","author":[{"given":"Prisca","family":"Guerra","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Di Cesare","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-7847","authenticated-orcid":false,"given":"Elia","family":"Rosi","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Scandagli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Silvi","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Nunziati","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-2045","authenticated-orcid":false,"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0001-7310(09)73373-3","article-title":"Cardiometabolic Comorbidities and the Approach to Patients with Psoriasis","volume":"100","author":"Gisondi","year":"2009","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","unstructured":"(2024, March 10). Otezla|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/otezla."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kosmas, C.E., Rodriguez Polanco, S., Bousvarou, M.D., Papakonstantinou, E.J., Pe\u00f1a Genao, E., Guzman, E., and Kostara, C.E. (2023). The Triglyceride\/High-Density Lipoprotein Cholesterol (TG\/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics, 13.","DOI":"10.3390\/diagnostics13050929"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gualtierotti, R., and De Lucia, O. (2019). Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report. JCM, 8.","DOI":"10.3390\/jcm8030398"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","article-title":"Effect of the Phosphodiesterase 4 Inhibitor Apremilast on Cardiometabolic Outcomes in Psoriatic Disease\u2014Results of the Immune Metabolic Associations in Psoriatic Arthritis Study","volume":"61","author":"Ferguson","year":"2021","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real Life Experience of Apremilast in Psoriasis and Arthritis Psoriatic Patients: Preliminary Results on Metabolic Biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement: A Phase III, Randomised, Controlled Trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and Safety of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Moderate-to-severe Plaque Psoriasis over 52 Weeks: A Phase III, Randomized Controlled Trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The Efficacy and Safety of Apremilast, Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: 52-week Results from a Phase IIIb, Randomized, Placebo-controlled Trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-Term Safety and Tolerability of Apremilast in Patients with Psoriasis: Pooled Safety Analysis for \u2265156 Weeks from 2 Phase 3, Randomized, Controlled Trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/joim.13447","article-title":"The Clinical and Molecular Cardiometabolic Fingerprint of an Exploratory Psoriatic Arthritis Cohort Is Associated with the Disease Activity and Differentially Modulated by Methotrexate and Apremilast","volume":"291","author":"Ruiz","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/idoj.IDOJ_169_19","article-title":"Real-World Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-Severe Psoriasis","volume":"11","author":"Shah","year":"2020","journal-title":"Indian. Dermatol. Online J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","article-title":"Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-Label, Nonrandomized Clinical Trial","volume":"158","author":"Gelfand","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcmg.2017.08.014","article-title":"Visceral Adiposity in Psoriasis Is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography\/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study","volume":"11","author":"Rivers","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e142534","DOI":"10.1172\/jci.insight.142534","article-title":"Chronic Inflammation in Psoriasis Promotes Visceral Adiposity Associated with Noncalcified Coronary Burden over Time","volume":"5","author":"Sajja","year":"2020","journal-title":"JCI Insight"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ijo.2015.64","article-title":"Effect of Lifestyle Weight Loss Intervention on Disease Severity in Patients with Psoriasis: A Systematic Review and Meta-Analysis","volume":"39","author":"Upala","year":"2015","journal-title":"Int. J. Obes."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and Psoriasis: Body Weight and Body Mass Index Influence the Response to Biological Treatment","volume":"25","author":"Puig","year":"2011","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"AB89","DOI":"10.1016\/j.jaad.2019.06.346","article-title":"Long-Term Hemoglobin A1c Changes with Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Pooled Analysis of Phase 3 ESTEEM and PALACE Trials and Phase 3b LIBERATE Trial","volume":"81","author":"Puig","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bcp.2008.07.025","article-title":"Phosphodiesterase 3 and 4 Comprise the Major cAMP Metabolizing Enzymes Responsible for Insulin Secretion in INS-1 (832\/13) Cells and Rat Islets","volume":"76","author":"Waddleton","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00125-012-2632-z","article-title":"The Glucose-Lowering Effects of the PDE4 Inhibitors Roflumilast and Roflumilast-N-Oxide in Db\/Db Mice","volume":"55","author":"Vollert","year":"2012","journal-title":"Diabetologia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E1720","DOI":"10.1210\/jc.2011-2886","article-title":"Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus","volume":"97","author":"Wouters","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1476-5381.2009.00194.x","article-title":"The Role of the PDE4D cAMP Phosphodiesterase in the Regulation of Glucagon-like Peptide-1 Release","volume":"157","author":"Ong","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ikonomidis, I., Pavlidis, G., Kadoglou, N., Makavos, G., Katogiannis, K., Kountouri, A., Thymis, J., Kostelli, G., Kapniari, I., and Theodoropoulos, K. (2022). Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020172"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2677","DOI":"10.1002\/brb3.2677","article-title":"Apremilast Exerts Protective Effects on Stroke Outcomes and Blood\u2013Brain Barrier (BBB) Dysfunction through Regulating Rho-associated Protein Kinase 2 Expression","volume":"12","author":"Wang","year":"2022","journal-title":"Brain Behav."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19012","DOI":"10.18632\/aging.103665","article-title":"Apremilast Ameliorates Ox-LDL-Induced Endothelial Dysfunction Mediated by KLF6","volume":"12","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/jdv.17769","article-title":"Apremilast Effectively Inhibits TNF\u03b1-induced Vascular Inflammation in Human Endothelial Cells","volume":"36","author":"Otto","year":"2022","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2017.01.056","article-title":"Early Detection of Left Ventricular Dysfunction in First-Degree Relatives of Diabetic Patients by Myocardial Deformation Imaging: The Role of Endothelial Glycocalyx Damage","volume":"233","author":"Ikonomidis","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Puertas-Umbert, L., Alonso, J., Hove-Madsen, L., Mart\u00ednez-Gonz\u00e1lez, J., and Rodr\u00edguez, C. (2023). PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242317017"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","article-title":"The Risks of Major Cardiac Events among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs or Corticosteroids","volume":"60","author":"Persson","year":"2021","journal-title":"Rheumatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of Major Adverse Cardiovascular Events in Patients Initiating Biologics\/Apremilast for Psoriatic Arthritis: A Nationwide Cohort Study","volume":"61","author":"Penso","year":"2022","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/obr.12385","article-title":"Phosphodiesterase-4 Inhibition as a Therapeutic Strategy for Metabolic Disorders","volume":"17","author":"Wu","year":"2016","journal-title":"Obes. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1006\/bbrc.2001.6259","article-title":"Cyclic AMP-Specific Phosphodiesterase 4 Inhibitors Promote ABCA1 Expression and Cholesterol Efflux","volume":"290","author":"Lin","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/3\/395\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:14:40Z","timestamp":1760105680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/3\/395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["life14030395"],"URL":"https:\/\/doi.org\/10.3390\/life14030395","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]}}}